Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
American Journal of PsychiatryPublished 1 April 1997
Gary D. Tollefson, Charles M. Beasley, P.V. Tran, J. Street, J A Krueger, R. Tamura
Citations897
SJR quartileQ1
SJR score5.27
SNIP3.68
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Olanzapine shows a superior and broader spectrum of efficacy in the treatment of schizophrenic psychopathology, with a substantially more favorable safety profile, than haloperidol and meets several of the criteria for a novel atypical antipsychotic agent.
Abstract
Olanzapine shows a superior and broader spectrum of efficacy in the treatment of schizophrenic psychopathology, with a substantially more favorable safety profile, than haloperidol. It meets several of the criteria for a novel atypical antipsychotic agent.
Keywords
Medicine
The British Journal of PsychiatryA New Depression Scale Designed to be Sensitive to Change
13,927 Citations1979Stuart Montgomery, Marie Åsberg
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.
Archives of General PsychiatryClozapine for the Treatment-Resistant Schizophrenic
4,090 Citations1988John M. Kane
In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.
Acta Psychiatrica ScandinavicaA RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
3,263 Citations1970G. M. Simpson, M. B. +4 more
A modification of an earlier rating scale for extrapyramidal system disturbance is described, and evidence for the validity and reliability of the scale is presented.
Encyclopedia of Sexual Behavior and the LawU.S. Department of Health and Human Services
3,193 Citations2006Of Family Growth, Public Health Service
ScienceDopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
2,229 Citations1976Ian Creese, David R. Burt +1 more
Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding, providing a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.
The British Journal of PsychiatryA Rating Scale for Drug-Induced Akathisia
2,175 Citations1989Thomas R. E. Barnes
NeuropsychopharmacologyRadioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
1,070 Citations1996Frank P. Bymaster, David O. Calligaro +6 more
The receptor binding profile of olanzapine is consistent with the antidopaminergic, antiserotonergic, and antimuscarinic activity observed in animal models and predicts atypical antipsychotic activity in man.
Schizophrenia BulletinThe Two-syndrome Concept: Origins and Current Status
833 Citations1985Timothy J. Crow
The two-syndrome concept postulates two "dimensions of pathology" underlying schizophrenia--a reversible (and potentially neuroleptic-responsive) component and a sometimes progressive and relatively irreversible component associated with the deficit state and poor long-term outcome.
NeuropsychopharmacologyOlanzapine versus Placebo and Haloperidol
787 Citations1996Charles M. Beasley, Gary D. Tollefson +4 more
The most common treatment-emergent adverse events included somnolence, agitation, asthenia, and nervousness.
American Journal of PsychiatryOne hundred years of schizophrenia: a meta-analysis of the outcome literature
761 Citations1994James D. Hegarty, Ross J. Baldessarini +3 more
Overall, less than half of patients diagnosed with schizophrenia have shown substantial clinical improvement after follow-up averaging nearly 6 years, despite considerable gains in improvement rates after mid-century, there has been a decline since the 1970s.
Archives of General PsychiatryNational Institute of Mental Health Longitudinal Study of Chronic Schizophrenia
629 Citations1991Alan Breier
Level of positive and negative symptoms ascertained when patients received optimal neuroleptic treatment during the index hospitalization significantly predicted outcome levels of symptoms and functioning and time spent hospitalized during the follow-up period, suggesting that treatment response is a critical predictor variable for the course of illness in schizophrenics.
The British Journal of PsychiatryRisperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol
553 Citations1995J. Peuskens
Risperidone is an effective antipsychotic for the treatment of chronic schizophrenia; doses of 4 and 8 mg seem to be optimal and have a lower incidence of side-effects than haloperidol.
PsychopharmacologyOlanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
404 Citations1996Charles M. Beasley, T.M. Sanger +4 more
Olanzapine appears to be not only safe and effective, but a promising atypical antipsychotic candidate.
Schizophrenia BulletinTreatment of Schizophrenia
322 Citations1987John M. Kane
Although no major "breakthrough" has occurred in the treatment of schizophrenia, incremental advances which can reduce rates of relapse and rehospitalization, improve the quality of adaptation, and reduce the risk of significant adverse effects are of enormous importance to affected individuals, their families, and society at large.
European NeuropsychopharmacologyOlanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
281 Citations1997Charles M. Beasley, S.H. Hamilton +6 more
Although olanzapine was associated with some increase in prolactin concentrations, increases were transient, occurred less often, and were of lesser magnitude than those observed with haloperidol.
PsychopharmacologyClozapine: neuroleptic-induced EPS and tardive dyskinesia
252 Citations1989Daniel E. Casey
American Journal of PsychiatryClozapine-induced weight gain: prevalence and clinical relevance
249 Citations1992R. Leadbetter, Michael S. Shutty +4 more
Clozapine's propensity to induce weight gain may relate to the drug's efficacy and/or its unique neuropharmacologic effects.
PsychopharmacologyAntipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors
248 Citations1995Roy Corbett, Fernando Camacho +5 more
Assessment of the effects of antipsychotic agents in the CMA, MK-801-LF and PCP-induced social withdrawal assays may provide a preclinical approach to identify novel agents for negative symptoms and treatment resistant schizophrenia.
NeuropsychopharmacologyA PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects
132 Citations1997Sigrid Nyberg
Extrapolation from the present observations after a 10 mg single-dose suggest, that at the lower end of the clinically examined dose range the D2 and 5-HT2 receptor occupancy should be similar to that induced by standard doses of clozapine.
NeuropsychopharmacologyElectrophysiological Effects of Olanzapine, a Novel Atypical Antipsychotic, on A9 and A10 Dopamine Neurons
123 Citations1996Marsha E. Stockton, Kurt Rasmussen
Olanzapine has selective effects on A10 versus A9 dopamine cells following acute and chronic administration, similar to the effects observed with clozapine and may play an important role in the atypical antipsychotic profile of olanZapine.
PsychopharmacologyDopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a123 IBZM single photon emission tomography (SPET) study
121 Citations1996Lyn S. Pilowsky, Geraldo F. Busatto +6 more
Preliminary evidence suggests olanzapine is another atypical antipsychotic drug in which therapeutic response is not associated with a high degree of striatal D2 receptor occupancy in vivo, and 123I iodobenzamide single photon emission tomography was used to estimate striatal dopamine D2 receptors binding in vivo.
Molecular PharmacologyPossible Role of Free Radical Formation in Clozapine (Clozaril)-Induced Agranulocytosis
111 Citations1991Volker Fischer, Johannes A. Haar +3 more
It can be concluded from these data that radical scavengers such as ascorbic acid, when coadministered with clozapine to patients, may reduce oxidative stress and protein adduct formation.
International Clinical PsychopharmacologyNew antipsychotics: the present status
101 Citations1995Jes Gerlach, L Peacock
According to this classification the new antipsychotics can be subdivided into three main categories: the relatively pure dopamine antagonists; the dopamine (D2)-serotonin (5-HT2)-norepinephrine (α1 ) antagonists (risperidone, ziprazidone and sertindole); and the multireceptor antagonists (clozapine, olanzapine and seroquel).
International Clinical PsychopharmacologyMotor and mental aspects of extrapyramidal syndromes
79 Citations1995Dympna Casey
With the advent of new and novel antipsychotic drugs that have low EPS liability, patients will have fewer side effects, be less non-compliant and more able to benefit from rehabilitation efforts.
International Clinical PsychopharmacologyNeurocircuitries and neurotransmitter interactions in schizophrenia
75 Citations1995Arvid Carlsson
An attempt to widen the perspective on schizophrenia and to go beyond the dopamine hypothesis is described, where several other neurotransmitters appear to play an important role in psychomotor activity and psychotogenesis.
Drug SafetyMetabolism of Clozapine† by Neutrophils
69 Citations1992Jack Uetrecht
It is found that several drugs associated with a relatively high incidence of drug-induced agranulocytosis are metabolised by activated neutrophils to chemically reactive metabolites, and it is believed that this metabolite could be a nitrenium ion.
Life SciencesEvaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo
46 Citations1994Susan K. Hemrick-Luecke, Harold D. Snoddy +1 more
Previous in vitro and in vivo data reporting nefazodone to be an antagonist at 5HT2A receptors, but fail to show inhibition of the 5HT uptake carrier in the same dose range are reported.
The Journal of Nervous and Mental DiseaseProblems in Classification of Schizophrenics as Neuroleptic Responders and Nonresponders
39 Citations1985John G. Csernansky, Jonathan Kaplan +1 more
The authors review the many clinical and pharmacological factors that affect neuroleptic response and complicate the classification of schizophrenic patients into responders and nonresponders and suggest the subtyping of patients on the basis of “positive” or “negative” symptoms and the presence or absence of brain atrophy may be particularly useful in predicting neurolepticism.
PsychopharmacologyCytotoxic effects of neuroleptic drugs
35 Citations1987WilliamH. Munyon, Richard Salo +1 more
The difference in cytotoxicity of the neuroleptic drugs observed in these experiments accounts in part for the increase in agranulocytosis and hepatotoxicity with thioridazine and chlorpromazine and for the lower incidence of these side effects with less toxic drugs.
Experimental Biology and MedicineCytotoxicity of Phenothiazines on Chang Liver Cells as Measured by Enzyme Leakage
27 Citations1969Carlos A. Dujovne, H. J. Zimmerman
The CPZ appeared more potent in its cytotoxic activity than did PZ, as demonstrated by the effectiveness at lower concentrations and the greater rapidity and amount of enzymes released from the cells at equal concentrations.